688065.SHG Cathay Biotech Inc
- Market cap
- CNY 28.3B
- P/E
- 44.6x
- P/B
- 1.51x
- ROE
- 4.2%
- Dividend yield
- 1.11%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688065.SHG undervalued?
Graham number688065.SHG trades 72.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cathay Biotech Inc fundamental analysis
No fundamental analysis for Cathay Biotech Inc yet.
Cathay Biotech Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cathay Biotech Inc
Cathay Biotech Inc., together with its subsidiaries, engages in the research, development, production, and sale of bio-based materials in China and internationally. The company offers biological long-chain diacids, including sebacic acid and octadecanedioic acid; bio-based polyamides; and bio-based pentamethylene diamine under the TERRYL and ECOPENT brands. It also provides digital solutions for electrification, automation, and digitization for biological manufacturing. The …
Full company profileCathay Biotech Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cathay Biotech Inc annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 929M | 1.36B | 1.76B | 1.92B | 1.50B | 2.36B | 2.44B | 2.11B | 2.96B | 3.30B | 3.80B |
| Gross Profit | 334M | 590M | 763M | 851M | 688M | 837M | 829M | 579M | 836M | 635M | 1.36B |
| Operating Income | 205M | 406M | 541M | 589M | 522M | 723M | 708M | 454M | 552M | 635M | 886M |
| EBITDA | 202M | 440M | 617M | 690M | 643M | 909M | 986M | 773M | 897M | 947M | 860M |
| Net Income | 145M | 333M | 466M | 479M | 458M | 595M | 553M | 367M | 489M | 566M | 745M |
| EPS | 0.40 | 0.92 | 0.93 | 0.94 | 0.84 | 1.02 | 0.95 | 0.63 | 0.84 | 0.83 | 1.03 |
| Balance Sheet | |||||||||||
| Total Assets | 1.66B | 3.13B | 4.84B | 5.98B | 12.1B | 16.2B | 17.8B | 18.8B | 19.0B | 23.9B | 24.6B |
| Total Liabilities | 439M | 937M | 1.68B | 1.34B | 651M | 1.51B | 2.79B | 4.06B | 3.92B | -21.2B | 3.02B |
| Shareholders' Equity | 1.22B | 2.20B | 3.16B | 4.64B | 10.4B | 10.7B | 10.9B | 11.2B | 11.5B | 21.2B | 17.8B |
| Cash & Short-term Investments | 350M | 135M | 243M | 1.23B | 7.04B | 9.63B | 6.30B | 5.39B | 5.35B | 9.01B | 9.30B |
| Total Debt | - | 77.1M | 128M | 300M | - | 744M | 1.13B | 1.78B | 1.86B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -129M | 53.4M | -10.3M | 360M | 515M | 594M | 804M | 569M | 821M | 404M | - |
| Capital Expenditure | 323M | 995M | 410M | 511M | 763M | 1.47B | 4.20B | 1.57B | 843M | 743M | 1.10B |
| Free Cash Flow | -452M | -942M | -420M | -152M | -248M | -880M | -3.39B | -1.00B | -22.4M | -339M | 397M |
| Ratios | |||||||||||
| ROE | 11.9% | 15.1% | 14.8% | 10.3% | 4.4% | 5.6% | 5.1% | 3.3% | 4.2% | 2.7% | 4.2% |
| ROA | 8.8% | 10.6% | 9.6% | 8.0% | 3.8% | 3.7% | 3.1% | 1.9% | 2.6% | 2.4% | 3.0% |
| Net Profit Margin | 15.7% | 24.4% | 26.5% | 25.0% | 30.6% | 25.2% | 22.7% | 17.3% | 16.5% | 17.2% | 19.6% |
| Debt to Equity | - | 0.04x | 0.04x | 0.06x | - | 0.07x | 0.10x | 0.16x | 0.16x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cathay Biotech Inc dividends
- Dividend yield
- 1.11%
- Forward dividend
- 0.45 CNY
- Payout ratio
- 55.4%
- Ex-dividend date
- Jul 29, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 313M | 0.46 | 55.4% |
| 2024 | CNY 141M | 0.24 | 28.8% |
| 2023 | CNY 105M | 0.18 | 28.6% |
| 2022 | CNY 187M | 0.32 | 33.9% |
| 2021 | CNY 333M | 0.57 | 56.1% |
| 2020 | CNY 3.87M | 0.01 | 0.8% |
| 2019 | CNY 121M | 0.24 | 25.3% |
| 2018 | 179M | 0.36 | 38.4% |
| 2017 | 95.0K | 0.00 | 0.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Jul 20, 2022.
Who owns Cathay Biotech Inc
- Insiders 67.35%
- Institutions 2.34%
- Public & others 30.31%
- Shares outstanding 721M
- Free float 305M
Cathay Biotech Inc company profile
- Company name
- Cathay Biotech Inc
- Ticker
- 688065.SHG
- ISIN
- CNE100004447
- Exchange
- Shanghai Stock Exchange
- Sector
- Basic Materials
- Industry
- Chemicals
- Employees
- 1,844
- Fiscal year end
- December
- Address
- Building 11, Shanghai, China, 201114
- Phone
- 86 21 5080 1916
- Website
- cathaybiotech.com
About Cathay Biotech Inc
Cathay Biotech Inc., together with its subsidiaries, engages in the research, development, production, and sale of bio-based materials in China and internationally. The company offers biological long-chain diacids, including sebacic acid and octadecanedioic acid; bio-based polyamides; and bio-based pentamethylene diamine under the TERRYL and ECOPENT brands. It also provides digital solutions for electrification, automation, and digitization for biological manufacturing. The company's products are used in textiles, pharmaceuticals, automobiles, electronic appliances, consumer goods, engineering materials, and other industries. It exports its products. The company was incorporated in 2000 and is headquartered in Shanghai, China.
Cathay Biotech Inc management
8- Dr. Xiucai LiuChairman & President · born 1957
- Ms. Huiqing ZangVP, Secretary of the Board of Directors & Vice Chairman · born 1974
- Mr. Chen YangVP, Core Technician, COO & Director · born 1985
- Mr. Yijun DuVice President · born 1965
- Mr. Jun ZuoVice President · born 1979
- Mr. Hong Guang ZhangVice President · born 1968
- Mr. Benliang HouVice President · born 1967
- Xiao Kun ChenAccounting Supervisor